Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

16.35 +0.05 (+0.31%)
Streaming Delayed Price Updated: 11:43 AM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zai Lab Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
Zai Lab Announces Participation in September Investor Conferences
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Second Quarter 2024 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
News headline image
Why Is Zynex (ZYXI) Stock Down 24% Today? ↗
Zynex stock is falling on Friday as ZYXI investor react to earnings misses and poor guidance for Q3 and the full year of 2024. 
Via InvestorPlace
Topics Earnings
News headline image
Why Is DexCom (DXCM) Stock Down 38% Today? ↗
DexCom stock is up on Friday as DXCM investors react to the company's latest earnings report and its lackluster 2024 guidance. 
Via InvestorPlace
News headline image
Trade of the Day: Zai Lab (ZLAB) Stock Is a Possible Hidden Gem ↗
A compelling hidden-gem opportunity, Zai Lab’s groundbreaking cancer therapeutic and discounted valuation could drive up ZLAB stock. 
Via InvestorPlace
News headline image
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
From Zai Lab Limited
Via Business Wire
News headline image
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Participation in May and June Investor Conferences
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
From Zai Lab Limited
Via Business Wire
News headline image
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:ZLAB),(NASDAQ:NTBL),(NASDAQ:CRDF),(NYSE:JNJ) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Pre-market stock movers are a hot topic this morning and we've got traders covered with all of the news behind these movements on Thursday! 
Via InvestorPlace
News headline image
ZLAB Stock Earnings: Zai Lab Beats EPS, Beats Revenue for Q1 2024 ↗
ZLAB stock results show that Zai Lab beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
From Zai Lab Limited
Via Business Wire
News headline image
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion ↗
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates... 
Via Talk Markets
News headline image
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
From Zai Lab Limited
Via Business Wire
News headline image
One Good, One Bad News For Bristol Myers Squibb's Marketed Drugs: Details ↗
Bristol Myers Squibb shares update on Phase 3 YELLOWSTONE trial for Zeposia (ozanimod) in Crohn's disease. Primary endpoint not met, safety consistent. Also, positive Phase 3 results for Krazati... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.